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We report that the A103R protein of Chlorella virus PBCV-1 is an mRNA capping enzyme that catalyzes the
transfer of GMP from GTP to the 5* diphosphate end of RNA. This is a two-step reaction in which the enzyme
first condenses with GTP to form a covalent enzyme-GMP intermediate and then transfers the GMP to an RNA
acceptor to form a GpppN cap. Purified recombinant A103R is a 38-kDa monomer that lacks RNA (guanine-7-)
methyltransferase activity. With respect to its size, amino acid sequence, and biochemical properties, A103R
is more closely related to the yeast RNA guanylyltransferases than it is to the multifunctional capping enzymes
coded for by other large DNA viruses—the poxviruses and African swine fever virus. We surmise that in order
to cap its transcripts, PBCV-1 must either encode additional 5* processing activities or else rely on the host alga
to provide these functions.
tions as vaccinia virus mRNAs (17). However, the cellular
guanylyltransferase and methyltransferase reactions are catalyzed by two distinct enzymes encoded by separate genes (10,
15). The 50-kDa yeast cap methyltransferase includes a 205amino-acid segment with sequence similarity to the methyltransferase domain of vaccinia virus D1 (10). The cellular gene
encoding RNA guanylyltransferase has been identified in two
organisms—Saccharomyces cerevisiae and Schizosaccharomyces
pombe (15, 19). The 402-amino-acid S. pombe capping enzyme
is 38% identical to the guanylyltransferase from S. cerevisiae
(19). The sequence similarity of the two yeast guanylyltransferases and the D1-like proteins coded for by the DNA animal
viruses is limited to a set of six short collinear motifs that are
likely to constitute the nucleotidyl transferase active site (19,
20).
The theme that emerges from a comparison of the available
set of cap synthesis genes is that capping enzymes coded for by
animal DNA viruses are large multifunctional polypeptides
which consist of modular domains whereas the cellular capping
enzymes are smaller and more functionally discrete. Sequence
comparisons suggest that the DNA virus-encoded and cellular
enzymes are divergent branches on a phylogenetic tree. We
were intrigued, therefore, by the recent finding of a potential
RNA guanylyltransferase homolog coded for by Paramecium
bursaria Chlorella virus-1 (PBCV-1) (7). PBCV-1 is the prototype of a family of large polyhedral DNA viruses that replicate
in certain unicellular eukaryotic Chlorella-like green algae
(23). The PBCV-1 genome, like the genomes of the poxviruses
and ASFV, is a linear double-stranded DNA molecule with
inverted terminal repeats and covalently closed hairpin telomeres. The sequence of 55% of the 330-kbp PBCV-1 genome
has been reported (7–9); the virus is estimated to encode ;340
genes.
PBCV-1 gene A103R encodes a putative polypeptide which
includes each of the six motifs shared among the cellular and
DNA virus-encoded guanylyltransferases discussed above. The
predicted 330-amino-acid A103R protein displays 24 to 25%
amino acid identity overall with the S. cerevisiae and S. pombe
guanylyltransferases (7). Remarkably, there is little sequence
conservation with the guanylyltransferase domains of the poxvirus capping enzymes exclusive of the six short motifs. Potentially interesting questions about the evolution of the capping

Animal viruses have played a pivotal role in defining the
structure of the mRNA cap and the biochemistry of cap formation (1). Ensinger and colleagues (2) showed in 1975 that
the capping of vaccinia virus mRNAs occurs by a series of
three enzymatic reactions in which the 59 triphosphate terminus of the transcript first cleaves to a diphosphate-terminated
RNA by RNA triphosphatase and then is capped with GMP by
RNA guanylyltransferase and methylated at the N-7 position
of guanine by RNA (guanine-7-) methyltransferase. This same
pathway is used by reovirus and all cellular capping systems
that have been examined to date (1, 17), although exceptions
to this scheme have been noted for certain RNA viruses (1,
20).
An enzyme that catalyzes all three steps in cap formation has
been purified from vaccinia virus particles (12, 21, 24). The
capping enzyme is a heterodimer of 95- and 33-kDa subunits
encoded by the viral D1 and D12 genes, respectively. There are
three distinct catalytic sites within the 844-amino-acid D1 subunit. The RNA triphosphatase and RNA guanylyltransferase
active sites are located within an amino-terminal 545-aminoacid module (13). The methyltransferase active site resides
within a 305-amino-acid module at the carboxyl terminus of D1
(11). The D12 subunit, which is catalytically inert, serves as a
stimulatory factor for the methyltransferase (11).
Several other DNA viruses encode homologs of the vaccinia
virus D1 protein. Shope fibroma virus (SFV) encodes an 836amino-acid polypeptide that is 60% identical to vaccinia virus
D1 (22). SFV and vaccinia virus, which are both poxviruses,
replicate within the cytoplasm of infected cells. African swine
fever virus (ASFV) encodes an 868-amino-acid protein that is
21% identical to D1 (14). ASFV is an icosahedral virus that has
both nuclear and cytoplasmic stages in its replication cycle.
Guanylyltransferase activity has been demonstrated for the
SFV and ASFV gene products (14, 22), but little is known
about the subunit structures of the native SFV and ASFV
enzymes or their associated activities. It is presumed that the
SFV and ASFV guanylyltransferases possess triphosphatase
and methyltransferase activities.
Cellular transcripts are capped by the same series of reac-
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enzymes are raised, and these questions can be addressed once
the biochemical properties of the PBCV-1 A103R protein have
been defined.
In order to determine which activities, if any, are associated
with the PBCV-1 A103R protein, we expressed A103R in
Escherichia coli and purified the recombinant protein to apparent homogeneity. We demonstrate that A103R is indeed an
RNA guanylyltransferase that catalyzes the transfer of GMP
from GTP to the 59 diphosphate end of an RNA acceptor to
form the cap structure GpppN. A103R does not catalyze cap
methylation. In this regard, and with respect to its donor specificity, the Chlorella virus enzyme is more closely related to the
cellular guanylyltransferases than it is to the capping enzymes
coded for by other DNA viruses.
MATERIALS AND METHODS
T7-based vector for expression of PBCV-1 capping enzyme in bacteria. The
PBCV-1 A103R gene was amplified from a plasmid template containing a viral
genomic DNA fragment by PCR (7). Oligonucleotide primers complementary to
the 59 and 39 ends of the gene were designed to introduce NdeI restriction sites
at the translation initiation codon and immediately 39 of the translation stop
codon. The sequence of the 59 flanking primer was 59-ACATAATTATTACAT
ATGGTTCCTCCCACAATCAAC and that of the 39 flanking primer was 59-A
TAAACGTGACATCATATGTTAGTAACAACCATA. PCR was carried out
with Pfu DNA polymerase (Stratagene). The PCR product was digested with
NdeI and then inserted into the NdeI site of T7-based expression plasmid pET3c
(Novagen). The resulting plasmid, pET-A103R, was transformed into E. coli
BL21(DE3).
Expression and purification of recombinant A103R protein. A 500-ml culture
of E. coli BL21(DE3)/pET-A103R was grown at 378C in Luria-Bertani medium
containing 0.1 mg of ampicillin per ml until the A600 reached 0.5. The culture was
adjusted to 0.4 mM isopropyl-b-D-thiogalactopyranoside (IPTG), and incubation
was continued at 378C for 4 h. Cells were harvested by centrifugation, and the
pellet was stored at 2808C. All subsequent procedures were performed at 48C.
Thawed bacteria were resuspended in 100 ml of buffer A (50 mM Tris HCl [pH
7.5], 10% sucrose) containing 0.15 M NaCl. The sample was sonicated for 30 s
and then adjusted to 0.1% Triton X-100. The suspension was frozen on dry ice
and then allowed to thaw at 48C. Sonication was then repeated. A second round
of freezing, thawing, and sonication ensued. The lysate was separated into soluble and insoluble fractions by centrifugation for 45 min at 18,000 rpm with a
Sorvall SS34 rotor. The soluble extract (63 mg of protein) containing recombinant A103R protein was adjusted to 50 mM NaCl by the addition of 2 volumes
of buffer A and then applied to a 35-ml column of DEAE-cellulose that had been
equilibrated with buffer A containing 50 mM NaCl. The flowthrough fraction (25
mg of protein) was applied to a 15-ml column of phosphocellulose that had been
equilibrated in buffer A containing 50 mM NaCl. The column was washed with
the same buffer and then eluted stepwise with buffer B (50 mM Tris HCl [pH
8.0], 10% glycerol) containing 0.1, 0.2, 0.3, 0.4, 0.5, and 1.0 M NaCl. A103R was
retained on the column and was recovered predominantly in the 0.4 M fraction
(5 mg of protein). Enzyme fractions were stored at 2808C and thawed on ice just
prior to use. The protein concentration of the phosphocellulose enzyme preparation was determined by UV absorbance according to the following formula:
protein (in milligrams per milliliter) 5 1.55(A280) 2 0.76(A260).
Enzyme-GMP (EpG) complex formation. Standard reaction mixtures (20 ml)
containing 50 mM Tris HCl (pH 8.5), 5 mM dithiothreitol (DTT), 5 mM MgCl2,
1 mM [a-32P]GTP, and enzyme were incubated for 5 min at 378C, and then the
reaction was halted by the addition of sodium dodecyl sulfate (SDS) (1% final
concentration). The samples were electrophoresed through a 12% polyacrylamide gel containing 0.1% SDS. Label transfer to the 38-kDa A103R polypeptide was visualized by autoradiographic exposure of the dried gel and was quantitated by scanning the gel with a FUJIX BAS1000 Bio-Imaging Analyzer.
Glycerol gradient sedimentation. An aliquot (40 mg) of the phosphocellulose
A103R preparation was applied to a 4.8-ml, 15 to 30% glycerol gradient containing 50 mM Tris HCl (pH 8.0) and 0.5 M NaCl. The gradient was centrifuged
at 50,000 rpm for 24 h at 48C with a Beckman SW50 rotor. Fractions (0.22 ml)
were collected from the bottom of the tube. Aliquots of every other fraction were
assayed for EpG formation activity. The polypeptide composition of the gradient
fraction was examined by SDS-polyacrylamide gel electrophoresis (PAGE).
Marker proteins, vaccinia virus capping enzyme, bovine serum albumin, and
cytochrome c were sedimented in a parallel gradient.
Isolation of capping enzyme-[32P]GMP complex by gel filtration. Reaction
mixtures (50 ml) containing 50 mM Tris HCl (pH 8), 5 mM DTT, 5 mM MgCl2,
1 mM [a-32P]GTP, and either 1 mg of A103R protein or 2.5 mg of vaccinia virus
capping enzyme (D1-D12 hetrodimer) were incubated for 5 min at 378C. The
samples were adjusted to 20 mM EDTA and 10% glycerol. Native EpG complex
was resolved from free GTP by gel filtration through a 1-ml column of Sephadex
G-50 that had been equilibrated with buffer B containing 50 mM NaCl; gel
filtration was performed at 48C. Three-drop fractions (;120 ml) were collected
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serially; the elution profile was determined by Cerenkov counting of each fraction.
Preparation of RNA substrates. g-32P-labeled triphosphate-terminated
poly(A) was synthesized as described previously (21) and then converted to 59
diphosphate-terminated poly(A) by treatment with vaccinia virus capping enzyme. The RNA triphosphatase reaction mixture (0.2 ml) containing 50 mM Tris
HCl (pH 8.0), 5 mM DTT, 5 mM MgCl2, 500 pmol of g-32P-labeled triphosphateterminated poly(A), and 50 pmol of purified recombinant vaccinia virus capping
enzyme was incubated for 1 h at 378C. The quantitative release of 32Pi from
poly(A) was verified by polyethyleneimine-cellulose thin-layer chromatography.
The RNA product was then recovered by two rounds of precipitation with 10%
trichloroacetic acid. The poly(A) was resuspended in 0.1 M Tris HCl, pH 8.0, and
then extracted with phenol-chloroform, ethanol precipitated, and resuspended in
100 ml of 10 mM Tris HCl (pH 8.0)–1 mM EDTA.
Cap-labeled poly(A) [GpppA(pA)n] and methylated cap-labeled poly(A)
[m7GpppA(pA)n] were prepared by the transfer of [32P]GMP from [a-32P]GTP
to triphosphate-terminated poly(A) by using purified vaccinia virus capping enzyme. Reaction mixtures (50 ml) contained 50 mM Tris-HCl (pH 8.0), 2 mM
MgCl2, 5 mM DTT, 50 pmol of triphosphate-terminated poly(A), 4 mM
[a-32P]GTP, and 0.5 mg of purified recombinant vaccinia virus capping enzyme
(D1-D12 heterodimer) and were supplemented with either 10 mM S-adenosylhomocysteine [for preparation of m7GpppA(pA)n] or 50 mM S-adenosylmethionine (AdoMet) [for preparation of m7GpppA(pA)n]. After incubation for 30
min at 378C, unincorporated GTP was removed by multiple rounds of trichloroacetic acid precipitation. The RNA was extracted with phenol-chloroform and
recovered by ethanol precipitation. Recovery of labeled RNA was assessed by
scintillation counting. The molar concentration of cap-labeled RNA was calculated according to the specific activity of the input [a-32P]GTP donor.

RESULTS
Expression of the PBCV-1 A103R protein in bacteria. The
amino acid sequence similarity of the A103R open reading
frame of Chlorella virus PBCV-1 and the RNA capping enzymes of S. cerevisiae and S. pombe suggested that A103R
might possess guanylyltransferase activity. To test this possibility, we expressed the A103R protein in bacteria under the
transcriptional control of a bacteriophage T7 promoter. The
pET-A103R expression plasmid was introduced into E. coli
BL21(DE3), a strain that contains the T7 RNA polymerase
gene under the control of a lacUV5 promoter. A 38-kDa
polypeptide doublet corresponding to A103R was detectable
by SDS-PAGE in whole-cell extracts of IPTG-induced bacteria
(Fig. 1A, lane 1). This doublet was not present when bacteria
containing the pET vector alone were induced with IPTG
(data not shown). After centrifugal separation of the crude
lysate, A103R protein was recovered in the soluble supernatant fraction (Fig. 1A, lane 2).
Recombinant A103R forms a covalent protein-GMP complex in vitro. The mRNA guanylyltransferase reaction entails
two sequential nucleotidyl transfer steps (18). In the first step,
nucleophilic attack on the a-phosphate of GTP by the enzyme
results in the liberation of PPi and formation of a covalent EpG
intermediate. Hence, guanylyltransferase activity can be detected with high sensitivity and specificity, even in crude extracts, by label transfer from [a-32P]GTP to the enzyme. In
order to assay guanylyltransferase activity of the expressed
A103R protein, we incubated either whole-cell or soluble extracts of IPTG-induced BL21(DE3)/pET-A103R cells in the
presence of [a-32P]GTP and a divalent cation. This incubation
resulted in the formation of an SDS-stable nucleotidyl-protein
adduct that migrated as a single 38-kDa species during SDSPAGE (Fig. 1B, lanes 1 and 2). Labeling of this polypeptide
was not detected in extracts prepared from bacteria that lacked
the A103R gene (data not shown). We conclude that the expressed A103R protein is active in transguanylylation.
Purification of recombinant PBCV-1 guanylyltransferase.
The A103R protein was purified from soluble bacterial extract
by ion-exchange chromatography. The A103R polypeptide
doublet did not bind DEAE-cellulose at low ionic strength (50
mM NaCl). SDS-PAGE analysis of the DEAE flowthrough
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FIG. 1. Expression, purification, and guanylyltransferase activity of the
PBCV-1 A103R protein. (A) The polypeptide compositions of recombinant
A103R protein at sequential stages of purification were analyzed by SDS-PAGE.
Lane 1, whole cell lysate of IPTG-induced BL21(DE3)/pET-A103R; lane 2,
soluble lysate fraction; lane 3, DEAE-cellulose flowthrough fraction; lane 4, 0.4
M NaCl phosphocellulose eluate. The gel was fixed and stained with Coomassie
blue dye. The positions and sizes (in kilodaltons) of the coelectrophoresed
marker polypeptides are shown on the left. The position of the recombinant
capping enzyme polypeptide doublet (CE) is indicated on the right. (B) Guanylyltransferase activity. The reaction mixtures (20 ml) contained 50 mM Tris
HCl (pH 8.0), 5 mM DTT, 5 mM MgCl2, 1 mM [a-32P]GTP, and recombinant
A103R protein at various stages of purification. Lane 1, whole-cell lysate; lane 2,
soluble lysate; lane 3, DEAE-cellulose flowthrough; lane 4, 0.4 M NaCl phosphocellulose eluate. The reaction products were resolved by SDS-PAGE. An
autoradiograph of the dried gel is shown. The enzyme-[32P]GMP complex is
denoted by the arrow on the left. The positions and sizes (in kilodaltons) of
prestained marker polypeptides are indicated on the right.

fraction (Fig. 1A, lane 3) showed that most of the polypeptides
greater than 40 kDa in size were eliminated at this step. A103R
adsorbed to phosphocellulose and was recovered during step
elution with 0.4 M NaCl (Fig. 1A, lane 4). The phosphocellulose preparation was virtually homogeneous with respect to the
38-kDa A103R doublet. Approximately 5 mg of purified recombinant A103R protein was obtained from a 500-ml culture
of IPTG-induced bacteria.
The guanylyltransferase activity profile, assayed by formation of a 38-kDa protein-GMP complex, coincided with the
relative abundance of the A103R protein during the DEAEcellulose and phosphocellulose purification steps (Fig. 1B,
lanes 3 and 4, and other data not shown). When the phosphocellulose fraction was centrifuged through a 15 to 30% glycerol
gradient in 0.5 M NaCl, a single peak of guanylyltransferase
activity that coincided with the 38-kDa A103R doublet was
detected (data not shown). We estimated a sedimentation coefficient of 3.2S relative to marker proteins sedimented in a
parallel gradient (data not shown). This result suggested that
the PBCV-1 guanylyltransferase is a monomer of the A103R
protein.
Purified PBCV-1 guanylyltransferase is a mixture of free
and GMP-bound A103R protein. The A103R protein appeared
as a polypeptide doublet after being analyzed by SDS-PAGE;
this was the case at every stage of purification (Fig. 1A). The
faster-migrating species predominated in the phosphocellulose
preparation (Fig. 2, lane 1). We hypothesized that the two
polypeptides represented the free or unguanylylated enzyme
(E) and the guanylylated enzyme (EpG). If this is true, then
the two forms might be interconvertible in vitro. Indeed, the
faster-migrating species was converted quantitatively into the
slower-migrating species by incubation of the enzyme preparation in the presence of 1 mM GTP and magnesium (Fig. 2,
lane 2). This maneuver is predicted to drive the reaction equi-
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FIG. 2. Unguanylylated and GMP-bound A103R proteins are interconvertible in vitro. An aliquot (0.4 mg) of the phosphocellulose A103R protein was
incubated for 10 min at 378C in a reaction mixture containing 50 mM Tris HCl
(pH 8.5), 5 mM MgCl2, and 5 mM DTT (lane 1) supplemented with either 1 mM
GTP (lane 2) or 1 mM NaPPi (lane 3). The reactions were then adjusted to 25
mM EDTA and denatured in 1% SDS. The samples were analyzed by SDSPAGE. A Coomassie blue-stained gel is shown. The positions of the proteinGMP complex (EpG) and the unguanylylated A103R protein (E) are indicated
on the left. The positions of 45- and 32-kDa marker proteins are denoted on the
right.

librium toward EpG formation. Conversely, all of the slowermigrating polypeptide was shifted to the more rapidly migrating free protein after the enzyme was incubated with 1 mM PPi
and magnesium (Fig. 2, lane 3). It is well established in other
capping systems that incubation of EpG in the presence of PPi
liberates GTP by reversal of the guanylylation reaction (16, 18,
26). The results of this experiment illuminate two important
properties of the recombinant PBCV-1 guanylyltransferase: (i)
the reaction of GTP with guanylyltransferase is freely reversible, and (ii) essentially all of the protein in the purified A103R
preparation is catalytically competent in nucleotidyl transfer.
Characterization of the enzyme-guanylate formation reaction. The amount of EpG complex formed during a 5-min
incubation at 378C in the presence of 1 mM [a-32P]GTP was
proportional to the amount of added A103R protein (Fig. 3A).
We estimated, on the basis of the molar amount of GMP
label-transfer versus the molar amount of A103R added, that
;50% of the protein was converted to EpG. This value is
slightly less than the ;70% of the A103R molecules estimated
by SDS-PAGE to be initially in the unguanylylated form. Because the results in Fig. 2 show clearly that all of the free
enzyme can be converted to EpG in vitro, we suspect that the
underestimate of the molar fraction of reactive enzyme in the
experiment illustrated in Fig. 3A results from an overestimate
of the A103R protein concentration. A kinetic analysis of EpG
formation indicated that the reaction was completed within
20 s at either 25 or 378C. The level of EpG remained unchanged up to 10 min (data not shown).
EpG complex formation depended on a divalent cation cofactor. This requirement was satisfied by either magnesium or
manganese. The yield of EpG was proportional to the magnesium concentration from 0.1 to 1 mM and was maximal at 2 to
5 mM (Fig. 3B). Although manganese was a more effective
cofactor than magnesium at concentrations below 0.5 mM,
similar levels of EpG formation were seen at 1 to 5 mM of
either cation (Fig. 3B). Neither calcium, cobalt, copper, nor
zinc supported EpG formation when present at a 5 mM concentration (data not shown). PPi, a reaction product, inhibited
EpG formation. In a standard guanylyltransferase reaction
containing 1 mM [a-32P]GTP and 5 mM MgCl2, EpG formation was reduced by half at 50 mM PPi; .90% inhibition was
observed at 0.2 mM PPi (Fig. 3C). Pi had no effect on EpG
formation at a 5 mM concentration (data not shown). Activity
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FIG. 3. Characterization of the guanylyltransferase activity of A103R. (A) Protein titration. The reaction mixtures (20 ml) contained 50 mM Tris HCl (pH 8.5), 5
mM DTT, 5 mM MgCl2, 1 mM [a-32P]GTP, and A103R (phosphocellulose fraction). The extent of EpG formation (in picomoles) is plotted as a function of input
protein. The molarity of A103R was calculated from the protein concentration (in milligrams per milliliter, determined by UV absorbance), assuming 100% purity and
a molecular weight of 38,000. (B) Divalent cation requirement. The reaction mixtures (20 ml) contained 50 mM Tris HCl (pH 8.5), 5 mM DTT, 1 mM [a-32P]GTP, 50
ng of A103R (phosphocellulose fraction), and a divalent cation (either MgCl2 or MnCl2) as indicated. The extent of EpG formation (in picomoles; y axis) is plotted
as a function of divalent cation concentration. (C) Inhibition by PPi. The reaction mixtures (20 ml) contained 50 mM Tris HCl (pH 8.5), 5 mM DTT, 5 mM MgCl2,
1 mM [a-32P]GTP, 50 ng of A103R, and NaPPi as indicated. The yield of EpG (expressed relative to the amount of EpG formed in a control reaction lacking NaPPi)
is plotted as a function of PPi concentration.

in 50 mM Tris HCl buffer was optimal at pH 8.0 to 9.0; the
amount of EpG formed at pH 6.0 to 6.5 was ;50% of the
amount formed at pH 8.5 (data not shown).
Nucleotide specificity. The A103R protein reacted specifically with [a-32P]GTP (Fig. 4). The yield of EpG increased as
a function of GTP concentration and reached saturation at 1
mM [a-32P]GTP (Fig. 5A). Half-saturation was achieved at
;0.2 mM GTP (Fig. 5A). There was no label transfer to the
38-kDa polypeptide in the presence of [g-32P]GTP (Fig. 4).
Similarly, [g-32P]ATP failed to label the protein. Trace
amounts of protein-nucleoside monophosphate were formed
in a reaction mixture containing [a-32P]ATP in lieu of GTP.
We suspect that this outcome actually represents an attack by
the enzyme on [a-32P]ITP, which arises by spontaneous deamination of ATP. ITP is an effective substrate for capping by the
HeLa cell guanylyltransferase (25). Other ribonucleoside
triphosphates—[a-32P]CTP and [a-32P]UTP—were inert in
nucleotidyl transfer (Fig. 4).

FIG. 4. Nucleotide specificity. The reaction mixtures contained 50 mM Tris
HCl (pH 8.5), 5 mM DTT, 5 mM MgCl2, 50 ng of A103R, and 0.17 mM of
32
P-labeled nucleoside triphosphate as indicated (except for [g-32P]GTP, which
was included at 0.1 mM). Incubation was for 5 min at 378C. The reaction products
were resolved by SDS-PAGE. An autoradiograph of the dried gel is shown. The
position of the 38-kDa enzyme-nucleotide complex is indicated by the arrowhead
on the left. The specific activities of the nucleotides were as follows: [a-32P]GTP,
9.6 3 105 cpm/pmol; [a-32P]UTP, 8.4 3 105 cpm/pmol; [a-32P]CTP, 1.0 3 106
cpm/pmol; [a-32P]ATP, 1.0 3 106 cpm/pmol; [g-32P]GTP, 3.1 3 106 cpm/pmol;
[g-32P]ATP, 5.5 3 105 cpm/pmol; and [a-32P]dGTP, 3.6 3 105 cpm/pmol.

[a-32P]dGTP was an extremely poor donor for enzyme-guanylate formation by A103R compared with [a-32P]GTP (Fig. 4
and 5A), indicating that the PBCV-1 enzyme discriminates
between ribose and deoxyribose sugars. We estimate from the
nucleoside triphosphate titration experiment in Fig. 5A that

FIG. 5. Nucleotide sugar specificity in EpG formation. The reaction mixtures
(20 ml) contained 50 mM Tris HCl (pH 8.5), 5 mM MgCl2, 5 mM DTT,
[a-32P]GTP or [a-32P]dGTP as indicated, and either 50 ng of PBCV-1 guanylyltransferase (A) or 125 ng of purified vaccinia virus capping enzyme (B). Incubation was for 5 min at 378C. The extent of EpG formation is plotted as a
function of nucleoside triphosphate (NTP) concentration.
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FIG. 6. The A103R EpG complex is an intermediate in RNA capping. The
PBCV-1 and vaccinia virus enzyme-[32P]GMP complexes were prepared and
isolated by gel filtration as described in Materials and Methods. Aliquots (10 ml)
of the gel-filtered complexes were incubated for 5 min at 378C in reaction
mixtures (200 ml) containing 50 mM Tris HCl (pH 8.0), 2 mM MgCl2, 5 mM
DTT, and 50 pmol of diphosphate-terminated poly(A), with (1) or without (2)
50 mM AdoMet. The mixtures were then extracted once with phenol and once
with chloroform-isoamyl alcohol (24:1). RNA was recovered from the aqueous
phase by ethanol precipitation and resuspended in 30 ml of 10 mM Tris HCl (pH
8.0)–1 mM EDTA. Aliquots (4 ml) were digested in 30 mM sodium acetate (pH
5.2) with 5 mg of nuclease P1 (Boehringer Mannheim) for 60 min at 378C. The
digests were analyzed by thin-layer chromatography on polyethyleneimine-cellulose plates developed with 0.45 M ammonium sulfate. An autoradiogram of the
thin-layer chromatography plate is shown. The location of the origin (ori) and
the positions of GTP, GpppA, and m7GpppA are noted.

GTP is 300-fold more effective than dGTP in EpG formation.
This level of sugar specificity by the PBCV-1 guanylyltransferase is in marked contrast to that of the vaccinia virus guanylyltransferase, which readily utilizes dGTP in EpG formation
(Fig. 5B). Rather, the PBCV-1 enzyme resembles the human
capping enzyme in its extreme preference for GTP over dGTP
(25, 26).
RNA capping by PBCV-1 guanylyltransferase. Purified
A103R was incubated with [a-32P]GTP, and the enzyme[32P]GMP complex was isolated by gel filtration. The A103R[32P]GMP complex was then incubated with diphosphate-terminated poly(A) in the presence of magnesium. A parallel
reaction performed with purified vaccinia virus capping enzyme-[32P]GMP complex served as a positive control for cap
formation. The products of the capping reaction were extracted with phenol-chloroform to remove the radiolabeled
enzyme, and the RNA acceptor was recovered by ethanol precipitation. The RNA samples were digested with nuclease P1
and then were analyzed by polyethyleneimine-cellulose thinlayer chromatography. Nuclease P1 digestion of the PBCV-1
guanylyltransferase reaction product liberated a single radioactive species corresponding to cap dinucleotide GpppA (Fig.
6). The mobility of this species was identical to that of cap
dinucleotide synthesized by the vaccinia virus capping enzyme
and was clearly distinct from that of free GTP (Fig. 6). Formation of the GpppA dinucleotide depended on digestion of
the capping reaction product with nuclease P1; in undigested
samples, the label remained at the position of the origin during
thin-layer chromatography, as was expected for a polynucleotide (data not shown). These results substantiate A103R as an
RNA capping enzyme.
In the same experiment, we tested whether A103R has an
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FIG. 7. GMP transfer to A103R from capped poly(A). The reaction mixtures
(10 ml) contained 50 mM Tris HCl (pH 8.5), 5 mM DTT, 5 mM MgCl2, 10 fmol
of cap-labeled poly(A) [GpppA(pA)n] or methylated cap-labeled poly(A)
[m7GpppA(pA)n] as indicated above the lanes, and either 400, 200, 40, 20, 4, or
2 fmol of the phosphocellulose fraction of A103R (proceeding from left to right
within each titration series). Control reactions lacking A103R are shown in lanes
-E. After incubation for 15 min at 378C, the reactions were terminated by adding
SDS to 1%, and the samples were analyzed by SDS-PAGE. An autoradiograph
of the dried gel is shown. The positions of the EpG complex and the cap-labeled
poly(A) substrate are indicated on the left.

associated RNA (guanine-7-) methyltransferase activity. This
test was done by analyzing the cap structures synthesized in the
presence of AdoMet. The vaccinia virus capping enzyme again
served as a positive control. Inclusion of AdoMet in the vaccinia virus capping reaction resulted in the quantitative methylation of all capped ends, as was evinced by the release of the
more rapidly migrating m7GpppA dinucleotide after digestion
with nuclease P1 (Fig. 6). However, inclusion of AdoMet in the
PBCV-1 capping reaction elicited no detectable methylation of
the RNA cap (Fig. 6).
Transfer of GMP from the RNA cap to A103R. To confirm
that the A103R protein-GMP complex is an intermediate in
cap synthesis, we tested whether GMP could be transferred
from the RNA cap to the A103R protein via reversal of
the capping reaction. [a-32P]GMP-labeled capped poly(A)
was synthesized with the vaccinia virus capping enzyme,
[a-32P]GTP, and triphosphate-terminated poly(A). Methylated cap-labeled poly(A) was synthesized in a parallel reaction
containing AdoMet. The capped poly(A) products were recovered free of [a-32P]GTP by multiple rounds of precipitation
with trichloroacetic acid and then with ethanol; the radiochemical purity of the capped RNA was confirmed by thin-layer
chromatography (data not shown). The PBCV-1 guanylyltransferase was incubated with cap-labeled poly(A) [GpppA(pA)n]
in the presence of magnesium, and the reaction products were
analyzed by SDS-PAGE. The cap-labeled poly(A) migrated
near the bottom of the gel (Fig. 7, lane -E). Inclusion of the
A103R protein in the reaction resulted in label transfer to the
38-kDa A103R polypeptide. The extent of GMP transfer from
the cap to the protein was proportional to the amount of
A103R added (Fig. 7) and was completely dependent on the
inclusion of magnesium (data not shown). Nearly all of the
GMP was donated back to A103R under conditions of enzyme
excess (Fig. 7). Transfer of half the input label to protein was
achieved at ;5 nM A103R. These results indicate that the
second step of the guanylyltransferase reaction is freely reversible and that the PBCV-1 enzyme binds avidly to the capped
RNA product. After the PBCV-1 guanylyltransferase was incubated with methylated cap-labeled poly(A) [m7GpppA(pA)n] in the presence of magnesium, no transfer of m7GMP
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from RNA to protein was detected, even in enzyme excess
(Fig. 7). Thus, cap methylation renders the guanylyltransferase
reaction irreversible.
DISCUSSION
The PBCV-1 A103R gene encoding a putative mRNA guanylyltransferase was identified during sequencing of the viral
DNA genome (7). We have now shown that A103R is an RNA
capping enzyme. This result was achieved by expressing the
PBCV-1 protein in bacteria and purifying the protein to homogeneity. A103R, like other DNA virus and cellular capping
enzymes, catalyzes the transfer of GMP from GTP to the
diphosphate end of RNA to form a GpppN cap structure. Our
experiments indicate that this transfer occurs in two steps involving condensation of the enzyme with GTP to form a covalent EpG intermediate and then transfer of GMP from A103R
to the RNA acceptor to form the cap. Although release of PPi
as a reaction product in the first step was not demonstrated
directly in this study, the failure to detect label transfer to
A103R from [g-32P]GTP, plus the inhibition of EpG formation
by PPi, is consistent with this reaction scheme. Note that EpG
formation does not require the presence of an RNA cap acceptor and that GMP transfer to RNA from EpG occurs in the
absence of GTP. These results, together with the demonstration of the transfer of GMP from the capped RNA product to
A103R, establish that EpG is a true catalytic intermediate.
Thus, the PBCV-1 capping enzyme adheres to the same mechanism of covalent nucleotidyl transfer as the vaccinia virus
(18), reovirus (3), and cellular (4, 16, 26) guanylyltransferases.
In size and amino acid sequence, the A103R protein most
closely resembles the guanylyltransferases of S. cerevisiae and
S. pombe and is more distantly related to the capping enzymes
coded for by the poxviruses and ASFV. We find that the
biochemical properties of A103R are also more akin to those
of the cellular guanylyltransferases. First, A103R, like the human capping enzyme, has a strong preference for GTP over
dGTP in EpG formation (26). Although a direct comparison of
GTP and dGTP in EpG formation has not been reported for
the yeast guanylyltransferase, the finding that excess unlabeled
GTP, but not dGTP, inhibits yeast enzyme-[32P]GMP formation in vitro (4) suggests that the yeast enzyme displays the
same nucleotide sugar selectivity as the human and PBCV-1
proteins. In contrast, the vaccinia virus enzyme utilizes either
GTP or dGTP as a cap donor. (Note that differences between
virus-encoded and host-encoded capping enzymes in substrate
specificity may be useful in designing drugs that selectively
block capping of virus-encoded mRNAs.)
A second distinction between the vaccinia virus and PBCV-1
capping enzymes is the lack of an associated methyltransferase
activity. Whereas the native vaccinia virus enzyme catalyzed
quantitative methylation of the newly incorporated cap
guanosine in the presence of AdoMet, there was no detectable
cap methylation by recombinant A103R. We note that the
vaccinia virus D1 subunit alone has much weaker methyltransferase activity than the D1-D12 heterodimer (11). Although it
is possible that A103R might require a stimulatory subunit to
catalyze cap methylation, we believe that this is unlikely, because the A103R protein bears no resemblance to either the
yeast cap methyltransferase or the methyltransferase catalytic
domain of the vaccinia virus capping enzyme (10, 11). In its
lack of intrinsic methyltransferase activity, A103R again resembles the yeast and mammalian guanylyltransferases. This
resemblance raises some interesting issues about PBCV-1
mRNA synthesis in vivo. For example, if PBCV-1 mRNAs
contain a standard m7GpppN cap, then the virus must either
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encode a separate cap methyltransferase or else rely on the
host to provide this function. No homolog of the known cap
methyltransferases has been uncovered in the 55% of the
PBCV-1 genome DNA sequence already reported (7–9), and
no homolog is encoded within the remainder of the PBCV-1
genome (6).
RNA triphosphatase activity is intrinsic to vaccinia virus D1.
Biochemical studies of the cellular enzymes suggest that the
guanylyltransferase and triphosphatase activities isolated from
rat liver and from brine shrimp reside within a single polypeptide (27, 28). However, in S. cerevisiae, the RNA triphosphatase activity associated with the guanylyltransferase during
its isolation from yeast extracts actually resides within a
polypeptide subunit distinct from the guanylyltransferase (5).
To address whether the recombinant PBCV-1 A103R protein
possessed RNA triphosphatase activity, we assayed for the
release of 32Pi from g-32P-poly(A). We detected a very low
level of phosphate release by the phosphocellulose A103R
preparation that was independent of a divalent cation cofactor.
However, this activity did not cosediment precisely with
A103R during glycerol gradient centrifugation. In addition, we
were able to resolve the PBCV-1 guanylyltransferase from the
phosphate-releasing activity by adsorbing the phosphocellulose
A103R protein to an SP5PW column and eluting the protein
with a linear salt gradient. We conclude that the phosphatase
was a bacterial contaminant and surmise that the Chlorella
virus guanylyltransferase does not have an intrinsic RNA
triphosphatase activity. The implication, as discussed above for
cap methylation, is that g-phosphate cleavage of PBCV-1 transcripts is performed either by a separate virus-encoded enzyme
or by an activity provided by the host.
In conclusion, it is remarkable that PBCV-1 should encode
an mRNA capping enzyme that is structurally and functionally
more similar to the monofunctional yeast RNA guanylyltransferases than to the multifunctional capping enzymes coded for
by other large DNA viruses. It is conceivable that this similarity
of A103R to cellular guanylyltransferases is dictated by a
unique virus-host dynamic, whereby capping of PBCV-1
mRNAs entails the interaction of a virus-encoded component
(the guanylyltransferase) with triphosphatase and methyltransferases encoded by the host.
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